Associations of dietary intake and supplement use with post-therapy cognitive recovery in breast cancer survivors
ConclusionsOur results indicate that higher vegetable intake, tea drinking, and fish oil supplementation may help post-therapy cognitive recovery for cancer patients. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 9, 2018 Category: Cancer & Oncology Source Type: research

Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 9, 2018 Category: Cancer & Oncology Source Type: research

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer
ConclusionsOnce-daily seviteronel was generally well tolerated in women with and 450  mg QD was chosen as the RP2D. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 9, 2018 Category: Cancer & Oncology Source Type: research

Uptake of BRCA 1 / 2 and oncotype DX testing by medical and surgical oncologists
AbstractPurposeThe diffusion of genomic testing is critical to the success of precision medicine, but there is limited information on oncologists ’ uptake of genetic technology. We aimed to assess the frequency with which medical oncologists and surgeons orderBRCA 1/2 and Oncotype DX testing for breast cancer patients.MethodsWe surveyed 732 oncologists and surgeons treating breast cancer patients. Physicians were from Florida, New York, New Jersey, and Pennsylvania, and were listed in the 2010 AMA Masterfile or identified by patients.Results80.6% of providers orderedBRCA 1/2 testing at least sometimes and 85.4% order...
Source: Breast Cancer Research and Treatment - May 8, 2018 Category: Cancer & Oncology Source Type: research

Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database
ConclusionsOur study showed that neo-/adjuvant chemotherapy using T irrespective of previous chemotherapy (AC or non-AC) was associated with significantly increased risk of CHF compared with AC-based chemotherapy in Korean patients with early breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 8, 2018 Category: Cancer & Oncology Source Type: research

SNP rs2071095 in LincRNA H19 is associated with breast cancer risk
AbstractPurposeAn increasing number of long intergenic non-coding RNAs (lincRNAs) appear to play critical roles in cancer development and progression. To assess the association between SNPs that reside in regions of lincRNAs and breast cancer risk, we performed a large case-control study in China.MethodsWe carried out a two-stage case-control study including 2881 breast cancer cases and 3220 controls. In stage I, we genotyped 17 independent (r2 
Source: Breast Cancer Research and Treatment - May 8, 2018 Category: Cancer & Oncology Source Type: research

Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer
ConclusionsHR deficiency remains an important biomarker target and potentially effective adjunct to enhance immunogenicity of ‘immune cold’ TNBCs. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 7, 2018 Category: Cancer & Oncology Source Type: research

Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001 –2016)
ConclusionsLTS generally receive HER2-targeted therapies for periods of time longer than in clinical trials, but most LTS also had breaks in treatment. More research is needed to understand the effects of long-term treatment and to identify patients who may be able to safely discontinue HER2-targeted therapy. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 7, 2018 Category: Cancer & Oncology Source Type: research

A double-blind, randomised trial of a polyphenolic-rich nail bed balm for chemotherapy-induced onycholysis: the UK polybalm study
ConclusionThe polyphenolic-rich essential oils and plant-based waxes in this nail bed balm profoundly reduced chemotherapy-related nail damage and improved nail-related quality of life, compared to a control. A further analysis is planned combining this balm with nail bed cooling. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 7, 2018 Category: Cancer & Oncology Source Type: research

Tamoxifen-induced fatty liver disease in a Caucasian patient
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 7, 2018 Category: Cancer & Oncology Source Type: research

Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ
ConclusionsThe risk of IHD was lower for women with DCIS allocated to RT compared to non-irradiated women and to the comparison cohort, probably due to patient selection. Comparison of RT by laterality did not show any over-risk for irradiation of the left breast. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 5, 2018 Category: Cancer & Oncology Source Type: research

Incorporation of the technologist ’s opinion for arbitration of discrepant assessments among radiologists at screening mammography
AbstractPurposeWe determined whether the addition of the technologist ’s opinion may be helpful in deciding if discordant readings at blinded double reading should be recalled.MethodsA consecutive series of 99,013 digital screening mammograms, obtained between July 2013 and January 2015, were included. All mammograms were first interpreted by a technologist and then double read in a blinded fashion by a team of 13 screening radiologists. All concordant and discordant positive readings among radiologists were recalled.ResultsOut of 3562 recalls, 998 women were recalled after a discordant reading. Of these women, 337 (...
Source: Breast Cancer Research and Treatment - May 5, 2018 Category: Cancer & Oncology Source Type: research

Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients
ConclusionWe developed a unique prediction model (42GC) for late recurrence by focusing on the biological differences between breast cancers with early and late recurrence. Interestingly, patients in the late recurrence-like group by 42GC were at low risk for early recurrence. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 4, 2018 Category: Cancer & Oncology Source Type: research

Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)
ConclusionsThus far, three CDK 4/6 inhibitors —palbociclib, ribociclib, and more recently, abemaciclib—have been approved for use in the setting of HR+, HER2−, mBC.  The degrees to which these agents differ in terms of CDK4/6 affinity, side-effect profiles, dosing, degree of central nervous system (CNS) penetration, optimal use in combin ation with antiestrogen therapy, and across other subsets of breast cancer, remain an active area of investigation. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 4, 2018 Category: Cancer & Oncology Source Type: research

BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients
ConclusionsBRCA1/2 mutation status leads to better responses to neoadjuvant chemotherapy in breast cancer. Pathological complete response is the main predictor of disease-free survival and overall survival, independently ofBRCA1/2 mutation status. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 3, 2018 Category: Cancer & Oncology Source Type: research

A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer
The objective of the current study is to create and internally validate a prognostic scoring model to predict the long-term OS for de novo stage IV BC patients treated with LRT.MethodsWe included de novo stage IV BC patients reported to NCDB between 2004 and 2015. Patients were divided into LRT and no-LRT subsets. We randomized LRT subset to training and validation cohorts. In the training cohort, a seventeen-point prognostic scoring system was developed based on the hazard ratios calculated using Cox-proportional method. We stratified both training and validation cohorts into two “groups” [group 1 (0–7 p...
Source: Breast Cancer Research and Treatment - May 2, 2018 Category: Cancer & Oncology Source Type: research

Correction to: Secretomes reveal several novel proteins as well as TGF- β1 as the top upstream regulator of metastatic process in breast cancer
AbstractIn the original publication of the article, Acknowledgement section was missed out and Table  1 was published incompletely. The Acknowledgment and complete table 1 are given in this correction. The original article has been corrected. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - May 2, 2018 Category: Cancer & Oncology Source Type: research

Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients
ConclusionsAlthough RGCT yielded increased genetic counseling participation, this did not result in increased rates of pre-surgical genetic testing or impact surgical decisions. These data suggest that those patients most likely to opt for genetic testing at the time of diagnosis are being effectively identified by their surgeons. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 2, 2018 Category: Cancer & Oncology Source Type: research

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
AbstractPurposeTo investigate the efficacy and safety of doublet versus single-agent chemotherapy (CT) plus trastuzumab (H) as first-line therapy for human epidermal growth factor 2 receptor (HER2)-positive metastatic breast cancer (MBC).MethodsWe searched for randomized clinical trials (RCTs) that evaluated the treatment effects of single-agent or doublet CT+H as first-line therapies for HER2-positive MBC. The main outcomes measured for this study included the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). A meta-analysis and trial sequential analysis (TSA) were performed, and the...
Source: Breast Cancer Research and Treatment - March 6, 2018 Category: Cancer & Oncology Source Type: research

Associations between ALDH1A1 polymorphisms, alcohol consumption, and mortality among Hispanic and non-Hispanic white women diagnosed with breast cancer: the Breast Cancer Health Disparities Study
ConclusionsMultiple SNPs inALDH1A1 were associated with increased risk of mortality after BC. Future BC studies examining the relationship betweenALDH1A1 and mortality should consider the modifying effects of alcohol consumption and NA ancestry. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 6, 2018 Category: Cancer & Oncology Source Type: research

PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer
ConclusionOur study suggests that PRMT5 may play an important role in the doxorubicin resistance of breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 6, 2018 Category: Cancer & Oncology Source Type: research

Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer
AbstractBackgroundOver the last 20  years, aromatase inhibitors (AI) have been tested in clinical trials as first-line therapy for hormone receptor-positive (HR-positive) advanced breast cancer (ABC), firstly as experimental arms, when they proved to be effective, and recently as control arms. This analysis aims to evaluate trends i n progression-free survival (PFS) and time to progression (TTP) over time.Patients and methodsA literature review was conducted using the MEDLINE database to identify randomized controlled phase II or III trials which reported PFS or TTP of at least one arm using first-line AI HR-positive ...
Source: Breast Cancer Research and Treatment - March 6, 2018 Category: Cancer & Oncology Source Type: research

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
ConclusionsIn this randomized phase II trial, tailored dose adjuvant chemotherapy was feasible, without an increased risk for long-term adverse events after a median follow-up of 10  years. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 6, 2018 Category: Cancer & Oncology Source Type: research

Characterization of a novel germline BRCA1 splice variant, c.5332+4delA
ConclusionsOur results indicate that theBRCA1 c.5332+4delA variant contributes to cancer predisposition through disruption of normal mRNA splicing. We classify this variant as likely pathogenic. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 6, 2018 Category: Cancer & Oncology Source Type: research

Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics
ConclusionPercent MD partially mediated the associations between breast biopsy, nulliparity, age at first birth, and hormone therapy with risk of breast cancer, particularly among postmenopausal women, suggesting that these risk factors at least partially influence breast cancer risk through changes in breast tissue composition. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 3, 2018 Category: Cancer & Oncology Source Type: research

The risk of cardiovascular disease following breast cancer by Framingham risk score
ConclusionsAmong women with low CVD risk, women with breast cancer have a higher risk of CVD event than women without breast cancer. Overall, women with breast cancer have a higher risk of CVD mortality than women without breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 28, 2018 Category: Cancer & Oncology Source Type: research

Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer
ConclusionsMost SMNs were unrelated to treatment, and the 15-year incidence was similar to that of cancer in the SEER control group —findings that should be reassuring to patients. Further risk reduction is expected from prophylactic gynecologic surgery. Continued investigations into genetic links with melanoma are warranted. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 27, 2018 Category: Cancer & Oncology Source Type: research

Survival of breast cancer patients in rural Ethiopia
ConclusionThe majority of breast cancer patients treated with surgery in rural parts of western Ethiopia are diagnosed at advanced stage and have hormone receptor-positive disease. Nearly half of the patients die within 2  years. These findings underscore the need for provision of adjuvant hormonal therapy and for the establishment of pathology service including hormone receptor testing. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 26, 2018 Category: Cancer & Oncology Source Type: research

Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients
AbstractPurposeTo assess the predictive role of pretreatment ki67 and Ki67 changes in breast cancer (BC) patients treated with neoadjuvant chemotherapy (NAC) in various molecular subtypes.Methods1010 BC patients who had undergone anthracycline and taxane-based NAC from January 2012 to July 2017 were retrospectively analyzed. Clinical and pathological parameters of the patients were retrieved and the predictive factors for NAC response were evaluated.Results705 patients showed clinical response (cRes), and 131 patients acquired pathologic complete response (pCR). Patients with higher pretreatment Ki67 ( ≥ 14%), tumo...
Source: Breast Cancer Research and Treatment - February 26, 2018 Category: Cancer & Oncology Source Type: research

What to look for in cell-free DNA from breast cancer patients
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 26, 2018 Category: Cancer & Oncology Source Type: research

Cell-free DNA in breast cancer: a long way to go
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 26, 2018 Category: Cancer & Oncology Source Type: research

Taste and smell perception and quality of life during and after systemic therapy for breast cancer
ConclusionsMost taste and smell alterations recovered within 6  months after the end of chemotherapy for breast cancer, but not for patients receiving trastuzumab. These results highlight the importance of monitoring taste and smell alterations during and after treatment with chemotherapy and trastuzumab, as they may impact quality of life. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 23, 2018 Category: Cancer & Oncology Source Type: research

Effects of physical exercise on breast cancer-related secondary lymphedema: a systematic review
ConclusionThe evidence indicates that exercise can improve subjective and objective parameters in BCRL patients, with dynamic, moderate, and high-frequency exercise appearing to provide the most positive effects. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 22, 2018 Category: Cancer & Oncology Source Type: research

Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations
ConclusionIn India, socioeconomic inequality limiting access to treatment is a major factor towards increased cancer burden; therefore, incorporation of a cost-effective and comprehensive multi-gene test will be helpful in ensuring widespread implementation of genetic screening in the clinical practice for hereditary breast and/or ovarian cancers. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 22, 2018 Category: Cancer & Oncology Source Type: research

Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations
ConclusionsNeoadjuvant versus adjuvant with standard anthracycline- and taxane-containing regimens results in similar disease-free survival and overall survival among patients with stage I and II triple-negative breast cancer regardless of BRCA status. Further studies are needed to evaluate whether similar results are observed with newer agents. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 22, 2018 Category: Cancer & Oncology Source Type: research

Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient
ConclusionThis novel human breast cancer-bone metastasis cell line will be a useful model to study aspects of breast cancer biology, particularly metastasis-related changes from breast to bone. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 21, 2018 Category: Cancer & Oncology Source Type: research

Tumor-associated macrophages and crown-like structures in adipose tissue in breast cancer
AbstractPurposeWe aimed to evaluate macrophage infiltration and to identify the status of crown-like structures (CLSs) in mammary adipose tissue of human breast tissue in cases with and without breast cancer.MethodsBreast adipose tissue was obtained from reduction mammoplasty (N = 56, Group 1), non-neoplastic breast tissue of breast cancer patients (N = 84, Group 2), and breast cancer with adipose stroma (N = 140, Group 3). Immunohistochemical staining of CD68 and CD163 was performed, and the infiltrating macrophages and CLSs within breast adipose tissue were evaluated.ResultsGroup 3 had the l...
Source: Breast Cancer Research and Treatment - February 21, 2018 Category: Cancer & Oncology Source Type: research

Long-term survival and cure model following liver resection for breast cancer metastases
AbstractIntroductionLong-term survival is still rarely achieved with current systemic treatment in patients with breast cancer liver metastases (BCLM). Extended survival after hepatectomy was examined in a select group of BCLM patients.Patients and methodsHepatectomy for BCLM was performed in 139 consecutive patients between 1985 and 2012. Patients who survived  
Source: Breast Cancer Research and Treatment - February 20, 2018 Category: Cancer & Oncology Source Type: research

A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer
ConclusionWe have identified a novelGLI1 gene signature that is associated with worse clinical outcomes among the patients with Luminal A subtype of breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 20, 2018 Category: Cancer & Oncology Source Type: research

Factors associated with improved outcomes for metastatic inflammatory breast cancer patients
This study aims to determine indicators of prognosis, including primary tumor resection, for stage IV IBC patients.MethodsUsing the National Cancer Data Base, female patients diagnosed 2010 –2013 with unilateral a priori metastatic T4d invasive adenocarcinoma of the breast were identified. We conducted propensity score matched analysis to balance confounders of surgery versus no-surgery. Stratified log-rank test and double-robust estimation under the Cox model were used to assess the effect of surgery, and margins, on overall survival (OS) in the propensity score matched cohort.ResultsOf 1266 patients, 41% underwent ...
Source: Breast Cancer Research and Treatment - February 19, 2018 Category: Cancer & Oncology Source Type: research

Acute toxicity of intraoperative radiotherapy and external beam-accelerated partial breast irradiation in elderly breast cancer patients
AbstractBackground and purposeWe investigated the acute toxicity of accelerated partial breast irradiation using external beam (EB-APBI) or intraoperative radiotherapy (IORT) techniques in elderly breast cancer patients.Materials and methodsWomen  ≥ 60 years with unifocal breast tumors of ≤ 30 mm were eligible for this prospective multi-center cohort study. IORT was applied with electrons following lumpectomy (23.3 Gy). EB-APBI was delivered using 3D-CRT or IMRT in 10 daily fractions of 3.85 Gy within 6 weeks after surgery. Acut e toxicity was scored using the CTCAE v3.0 a...
Source: Breast Cancer Research and Treatment - February 19, 2018 Category: Cancer & Oncology Source Type: research

Metastasis of breast cancer prior to invasion
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 19, 2018 Category: Cancer & Oncology Source Type: research

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)
AbstractPurposeAromatase inhibitors are the most commonly prescribed adjuvant endocrine therapy for hormone-dependent early breast cancer in postmenopausal women. Among Canadian Cancer Trials Group MA.27 participants, anastrozole and exemestane had comparable 5-year event-free survival. This companion study examined differences in patient-reported treatment-related symptoms (TRS) and health-related quality of life (HRQL) among postmenopausal women randomized to anastrozole or exemestane.MethodsMA.27 participants (N = 686, of 7576) randomized to 5 years of anastrozole (1 mg/day,n = 371, Arm A) or ex...
Source: Breast Cancer Research and Treatment - February 17, 2018 Category: Cancer & Oncology Source Type: research

Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy
ConclusionsThis study provides a rationale for the further development of PSMA-targeted imaging in breast cancer, especially in triple-negative tumors. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 17, 2018 Category: Cancer & Oncology Source Type: research

Safety and feasibility of breast lesion localization using magnetic seeds (Magseed): a multi-centre, open-label cohort study
ConclusionsMagnetic seeds are a feasible and safe method of breast lesion localization. They can be accurately placed, demonstrate no migration in this feasibility study and are detectable in all sizes and depths of breast tissue. Now that safety and feasibility have been demonstrated, further clinical studies are required to evaluate the seed ’s effectiveness in wide local excision surgery. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 16, 2018 Category: Cancer & Oncology Source Type: research

Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population
AbstractPurposeWe sought to disentangle the effects of statins and other lipid-lowering drugs and the underlying dyslipidemia for which they are prescribed on breast cancer risk.MethodsWe conducted a case –control study within the linked Surveillance, Epidemiology, and End results (SEER)-Medicare data. Cases were women with invasive breast cancer aged 66 + years (N = 30,004) identified by SEER registries (years 2007–2011). Controls were women (N = 198,969) identified from a 5% random sample of Medicare recipients alive and breast cancer free in year of selection. Participants had a...
Source: Breast Cancer Research and Treatment - February 15, 2018 Category: Cancer & Oncology Source Type: research

A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis
ConclusionsIn the SEER database, we observed far more deaths from DCIS than would be expected under a model where all deaths from breast cancer occur amongst women who experience an invasive local recurrence. This lends support to the hypothesis that DCIS mortality is not restricted to those women who experience an in-breast invasive cancer and that DCIS has properties similar to small invasive breast cancers. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 14, 2018 Category: Cancer & Oncology Source Type: research

Differences in breast cancer incidence among young women aged 20 –49 years by stage and tumor characteristics, age, race, and ethnicity, 2004–2013
In this study, we examined recent trends and variations in breast cancer incidence among young women in the United States.MethodsUsing 2004 –2013 National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program data, we calculated breast cancer incidence rates and trends and examined variations in stage, grade, and tumor subtype by age and race/ethnicity among young women aged 20–49 years.ResultsThe majority of breast cancer cases occurred in women aged 40 –44 and 45–49 years (77.3%). Among women aged 
Source: Breast Cancer Research and Treatment - February 14, 2018 Category: Cancer & Oncology Source Type: research

Evaluation of [ 89 Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer
Conclusions[89Zr]trastuzumab has the potential to characterize the HER2 status of the complete tumor burden in patients with breast cancer, thus obviating repeat or multiple tissue sampling to assess intrapatient heterogeneity of HER2 status. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 13, 2018 Category: Cancer & Oncology Source Type: research

The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery
ConclusionMBI seems to be a useful imaging modality with a high predictive value in revealing ipsilateral and bilateral disease not visualized by mammography and ultrasound. It may play an important role in delineating the extent of the index lesion during preoperative planning. Incorporation of MBI in the clinical work-up as an adjunct modality to mammography and ultrasound may lead to better selection of patients who could benefit from BCS. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 13, 2018 Category: Cancer & Oncology Source Type: research